Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Common Equity: 2009-2024

Historic Common Equity for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$301.3 million.

  • Ironwood Pharmaceuticals' Common Equity rose 15.15% to -$264.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$264.2 million, marking a year-over-year increase of 15.15%. This contributed to the annual value of -$301.3 million for FY2024, which is 12.98% up from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Common Equity is -$301.3 million, which was up 12.98% from -$346.3 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Common Equity peaked at $652.4 million during FY2022, and registered a low of -$346.3 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was -$301.3 million (2024), whereas its average is $1.6 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Common Equity soared by 867.29% in 2021 and then tumbled by 153.08% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Common Equity stood at $62.6 million in 2020, then soared by 867.29% to $605.9 million in 2021, then rose by 7.67% to $652.4 million in 2022, then slumped by 153.08% to -$346.3 million in 2023, then increased by 12.98% to -$301.3 million in 2024.